SGAM
PLX icon

Smith Group Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Smith Group Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-459
Closed -$23K – 438
2013
Q2 		$23K Buy
+459
New +$24.4K ﹤0.01% 282

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Smith Group Asset Management's PLX Position: Q3 2013 in Review

Smith Group Asset Management sold out of Protalix BioTherapeutics (PLX) in Q3 2013, closing a stake of 459 shares — an estimated $23K sold.

Smith Group Asset Management first reported a position in PLX in Q2 2013 and held it in 1 quarter. The position peaked at $23K in Q2 2013. 47 funds tracked by Wall St. Rank hold PLX as of Q3 2013.

  • Smith Group Asset Management reported no remaining Protalix BioTherapeutics position as of Q3 2013 after selling out during the quarter.
  • Smith Group Asset Management sold 459 Protalix BioTherapeutics shares in Q3 2013, an estimated $23K.
  • Smith Group Asset Management first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 1 quarter.
  • Smith Group Asset Management's Protalix BioTherapeutics position peaked at $23K in Q2 2013.
  • 47 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2013.

Based on Smith Group Asset Management's 13F filing for Q3 2013, filed 29 Oct 2013.